Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Diagnostic Radiopharmaceuticals & Contrast Media market. The report considers 2020-2023 historic period, 2024 as base year, and 2025-2035 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Diagnostic Radiopharmaceuticals & Contrast Media market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through primary research and expert insights. Eternity Insights also uses paid databases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Diagnostic Radiopharmaceuticals & Contrast Media market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Diagnostic Radiopharmaceuticals & Contrast Media products across developed and developing countries of the world.
Key Research Highlights: Market Restraints
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Diagnostic Radiopharmaceuticals & Contrast Media products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Diagnostic Radiopharmaceuticals & Contrast Media market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Diagnostic Radiopharmaceuticals & Contrast Media development has been the leading industry trend of Diagnostic Radiopharmaceuticals & Contrast Media market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be witnessed from the increasing spending on research and development and growing number of new product approvals.
Global Diagnostic Radiopharmaceuticals & Contrast Media Market Size, 2020-2035 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2024 |
USD XX.XX Million |
| CAGR (2025 - 2035) |
XX.XX % |
| The Revenue forecast in 2035 |
USD XX.XX Million |
| Base year for estimation |
2024 |
| Historical data |
2020-2023 |
| Forecast period |
2025-2035 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2025 to 2035
|
| Report Coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
Radiopharmaceuticals, Contrast Media, Other |
| By Application Outlook |
Diagnostic, Therapeutic, Ionizing Radiation based Radioimaging, Non-Ionizing Radiation based Radioimaging |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Amag Pharmaceuticals, Bayer Healthcare, Bracco Imaging, Daiichi Sankyo, GE Healthcare, Guerbet, Lantheus, Mallinckrodt, Medtronic, Nordion |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Amag Pharmaceuticals
- Bayer Healthcare
- Bracco Imaging
- Daiichi Sankyo
- GE Healthcare
- Guerbet
- Lantheus
- Mallinckrodt
- Medtronic
- Nordion
Diagnostic Radiopharmaceuticals & Contrast Media Market, By Type
- Radiopharmaceuticals
- Contrast Media
- Other
Diagnostic Radiopharmaceuticals & Contrast Media Market, By Application
- Diagnostic
- Therapeutic
- Ionizing Radiation based Radioimaging
- Non-Ionizing Radiation based Radioimaging
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
1 Study Coverage
1.1 Diagnostic Radiopharmaceuticals & Contrast Media Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Diagnostic Radiopharmaceuticals & Contrast Media Market Size Growth Rate by Product
1.4.2 Radiopharmaceuticals
1.4.3 Contrast Media
1.5 Market by End User
1.5.1 Global Diagnostic Radiopharmaceuticals & Contrast Media Market Size Growth Rate by End User
1.5.2 Diagnostic
1.5.3 Therapeutic
1.5.4 Ionizing Radiation based Radioimaging
1.5.5 Non-Ionizing Radiation based Radioimaging
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Diagnostic Radiopharmaceuticals & Contrast Media Market Size
2.1.1 Global Diagnostic Radiopharmaceuticals & Contrast Media Revenue 2014-2025
2.1.2 Global Diagnostic Radiopharmaceuticals & Contrast Media Sales 2014-2025
2.2 Diagnostic Radiopharmaceuticals & Contrast Media Growth Rate by Regions
2.2.1 Global Diagnostic Radiopharmaceuticals & Contrast Media Sales by Regions
2.2.2 Global Diagnostic Radiopharmaceuticals & Contrast Media Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Diagnostic Radiopharmaceuticals & Contrast Media Sales by Manufacturers
3.1.1 Diagnostic Radiopharmaceuticals & Contrast Media Sales by Manufacturers
3.1.2 Diagnostic Radiopharmaceuticals & Contrast Media Sales Market Share by Manufacturers
3.1.3 Global Diagnostic Radiopharmaceuticals & Contrast Media Market Concentration Ratio (CR5 and HHI)
3.2 Diagnostic Radiopharmaceuticals & Contrast Media Revenue by Manufacturers
3.2.1 Diagnostic Radiopharmaceuticals & Contrast Media Revenue by Manufacturers (2017-2020)
3.2.2 Diagnostic Radiopharmaceuticals & Contrast Media Revenue Share by Manufacturers (2017-2020)
3.3 Diagnostic Radiopharmaceuticals & Contrast Media Price by Manufacturers
3.4 Diagnostic Radiopharmaceuticals & Contrast Media Manufacturing Base Distribution, Product Types
3.4.1 Diagnostic Radiopharmaceuticals & Contrast Media Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Diagnostic Radiopharmaceuticals & Contrast Media Product Type
3.4.3 Date of International Manufacturers Enter into Diagnostic Radiopharmaceuticals & Contrast Media Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Diagnostic Radiopharmaceuticals & Contrast Media Sales by Product
4.2 Global Diagnostic Radiopharmaceuticals & Contrast Media Revenue by Product
4.3 Diagnostic Radiopharmaceuticals & Contrast Media Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Diagnostic Radiopharmaceuticals & Contrast Media Breakdown Data by End User
6 North America
6.1 North America Diagnostic Radiopharmaceuticals & Contrast Media by Countries
6.1.1 North America Diagnostic Radiopharmaceuticals & Contrast Media Sales by Countries
6.1.2 North America Diagnostic Radiopharmaceuticals & Contrast Media Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Diagnostic Radiopharmaceuticals & Contrast Media by Product
6.3 North America Diagnostic Radiopharmaceuticals & Contrast Media by End User
7 Europe
7.1 Europe Diagnostic Radiopharmaceuticals & Contrast Media by Countries
7.1.1 Europe Diagnostic Radiopharmaceuticals & Contrast Media Sales by Countries
7.1.2 Europe Diagnostic Radiopharmaceuticals & Contrast Media Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Diagnostic Radiopharmaceuticals & Contrast Media by Product
7.3 Europe Diagnostic Radiopharmaceuticals & Contrast Media by End User
8 Asia Pacific
8.1 Asia Pacific Diagnostic Radiopharmaceuticals & Contrast Media by Countries
8.1.1 Asia Pacific Diagnostic Radiopharmaceuticals & Contrast Media Sales by Countries
8.1.2 Asia Pacific Diagnostic Radiopharmaceuticals & Contrast Media Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Diagnostic Radiopharmaceuticals & Contrast Media by Product
8.3 Asia Pacific Diagnostic Radiopharmaceuticals & Contrast Media by End User
9 Central & South America
9.1 Central & South America Diagnostic Radiopharmaceuticals & Contrast Media by Countries
9.1.1 Central & South America Diagnostic Radiopharmaceuticals & Contrast Media Sales by Countries
9.1.2 Central & South America Diagnostic Radiopharmaceuticals & Contrast Media Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Diagnostic Radiopharmaceuticals & Contrast Media by Product
9.3 Central & South America Diagnostic Radiopharmaceuticals & Contrast Media by End User
10 Middle East and Africa
10.1 Middle East and Africa Diagnostic Radiopharmaceuticals & Contrast Media by Countries
10.1.1 Middle East and Africa Diagnostic Radiopharmaceuticals & Contrast Media Sales by Countries
10.1.2 Middle East and Africa Diagnostic Radiopharmaceuticals & Contrast Media Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Diagnostic Radiopharmaceuticals & Contrast Media by Product
10.3 Middle East and Africa Diagnostic Radiopharmaceuticals & Contrast Media by End User
11 Company Profiles
11.1 Amag Pharmaceuticals
11.1.1 Amag Pharmaceuticals Company Details
11.1.2 Company Business Overview
11.1.3 Amag Pharmaceuticals Diagnostic Radiopharmaceuticals & Contrast Media Sales, Revenue and Gross Margin (2017-2020)
11.1.4 Amag Pharmaceuticals Diagnostic Radiopharmaceuticals & Contrast Media Products Offered
11.1.5 Amag Pharmaceuticals Recent Development
11.2 Bayer Healthcare
11.2.1 Bayer Healthcare Company Details
11.2.2 Company Business Overview
11.2.3 Bayer Healthcare Diagnostic Radiopharmaceuticals & Contrast Media Sales, Revenue and Gross Margin (2017-2020)
11.2.4 Bayer Healthcare Diagnostic Radiopharmaceuticals & Contrast Media Products Offered
11.2.5 Bayer Healthcare Recent Development
11.3 Bracco Imaging
11.3.1 Bracco Imaging Company Details
11.3.2 Company Business Overview
11.3.3 Bracco Imaging Diagnostic Radiopharmaceuticals & Contrast Media Sales, Revenue and Gross Margin (2017-2020)
11.3.4 Bracco Imaging Diagnostic Radiopharmaceuticals & Contrast Media Products Offered
11.3.5 Bracco Imaging Recent Development
11.4 Daiichi Sankyo
11.4.1 Daiichi Sankyo Company Details
11.4.2 Company Business Overview
11.4.3 Daiichi Sankyo Diagnostic Radiopharmaceuticals & Contrast Media Sales, Revenue and Gross Margin (2017-2020)
11.4.4 Daiichi Sankyo Diagnostic Radiopharmaceuticals & Contrast Media Products Offered
11.4.5 Daiichi Sankyo Recent Development
11.5 GE Healthcare
11.5.1 GE Healthcare Company Details
11.5.2 Company Business Overview
11.5.3 GE Healthcare Diagnostic Radiopharmaceuticals & Contrast Media Sales, Revenue and Gross Margin (2017-2020)
11.5.4 GE Healthcare Diagnostic Radiopharmaceuticals & Contrast Media Products Offered
11.5.5 GE Healthcare Recent Development
11.6 Guerbet
11.6.1 Guerbet Company Details
11.6.2 Company Business Overview
11.6.3 Guerbet Diagnostic Radiopharmaceuticals & Contrast Media Sales, Revenue and Gross Margin (2017-2020)
11.6.4 Guerbet Diagnostic Radiopharmaceuticals & Contrast Media Products Offered
11.6.5 Guerbet Recent Development
11.7 Lantheus
11.7.1 Lantheus Company Details
11.7.2 Company Business Overview
11.7.3 Lantheus Diagnostic Radiopharmaceuticals & Contrast Media Sales, Revenue and Gross Margin (2017-2020)
11.7.4 Lantheus Diagnostic Radiopharmaceuticals & Contrast Media Products Offered
11.7.5 Lantheus Recent Development
11.8 Mallinckrodt
11.8.1 Mallinckrodt Company Details
11.8.2 Company Business Overview
11.8.3 Mallinckrodt Diagnostic Radiopharmaceuticals & Contrast Media Sales, Revenue and Gross Margin (2017-2020)
11.8.4 Mallinckrodt Diagnostic Radiopharmaceuticals & Contrast Media Products Offered
11.8.5 Mallinckrodt Recent Development
11.9 Medtronic
11.9.1 Medtronic Company Details
11.9.2 Company Business Overview
11.9.3 Medtronic Diagnostic Radiopharmaceuticals & Contrast Media Sales, Revenue and Gross Margin (2017-2020)
11.9.4 Medtronic Diagnostic Radiopharmaceuticals & Contrast Media Products Offered
11.9.5 Medtronic Recent Development
11.10 Nordion
11.10.1 Nordion Company Details
11.10.2 Company Business Overview
11.10.3 Nordion Diagnostic Radiopharmaceuticals & Contrast Media Sales, Revenue and Gross Margin (2017-2020)
11.10.4 Nordion Diagnostic Radiopharmaceuticals & Contrast Media Products Offered
11.10.5 Nordion Recent Development
12 Future Forecast
12.1 Diagnostic Radiopharmaceuticals & Contrast Media Market Forecast by Regions
12.1.1 Global Diagnostic Radiopharmaceuticals & Contrast Media Sales Forecast by Regions 2019-2025
12.1.2 Global Diagnostic Radiopharmaceuticals & Contrast Media Revenue Forecast by Regions 2019-2025
12.2 Diagnostic Radiopharmaceuticals & Contrast Media Market Forecast by Product
12.2.1 Global Diagnostic Radiopharmaceuticals & Contrast Media Sales Forecast by Product 2019-2025
12.2.2 Global Diagnostic Radiopharmaceuticals & Contrast Media Revenue Forecast by Product 2019-2025
12.3 Diagnostic Radiopharmaceuticals & Contrast Media Market Forecast by End User
12.4 North America Diagnostic Radiopharmaceuticals & Contrast Media Forecast
12.5 Europe Diagnostic Radiopharmaceuticals & Contrast Media Forecast
12.6 Asia Pacific Diagnostic Radiopharmaceuticals & Contrast Media Forecast
12.7 Central & South America Diagnostic Radiopharmaceuticals & Contrast Media Forecast
12.8 Middle East and Africa Diagnostic Radiopharmaceuticals & Contrast Media Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Diagnostic Radiopharmaceuticals & Contrast Media Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
